TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria for NeoCirc-001, 001A and 001B -~Target population for informed consent:~* neonates 24 to 32+6 weeks´ gestation,~* postnatal age \<72 hours;~Infants eligible for circulatory failure pathway:~* parental informed consent obtained;~* The infants will be assessed, as per routine clinical practice, for clinical signs indicating infants at risk of poor perfusion, and will be recruited if they develop haemodynamic insufficiency defined as: either two or more of: (i) Mean blood pressure (MBP) \< gestational age (GA)-1 mmHg (invasive/non-invasive, two readings 15 min apart); (ii) SVC flow \< 51 ml/kg/min; (iii) capillary refill time (CRT) \> 4 sec; (iv) Lactate \> 4 mmol/l (v) Base excess \<-9 mmol/l or: MBP \< GA -5 mmHg (invasive/non-invasive, two readings 15 min apart)~Exclusion Criteria: NeoCirc-001, 001A and 001B -~* non-viability;~* congenital hydrops or malformations likely to affect cardiovascular adaptation;~* surgery planned within 72 hours of birth;~* chromosomal anomalies;~* informed consent form (ICF) not signed.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- Dobutamine (Type: EXPERIMENTAL): Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP® Tape)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Depending on study arm:~* Women with a TiLOOP® Tape implant, Implanted between 2007 and 2009 at the study center - OR -~* Woman with a planned Tape implantation at the study center - OR -~* Woman with no disease related to incontinence~* Subject is able to understand the nature, relevance and significance of the clinical trial~* Subject has given informed consent~Exclusion Criteria:~* Subject revoked consent~* Lack of subject's compliance regarding data collection or examination in the scope of the trial (Non-Compliance)~* Subject institutionalized by court or official order (MPG §20.3)~* Subject participates in another clinical investigation

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patients treated with a surgical mesh (Type: None): This arm of study patients is defined by patients treated with a TiLOOP® Tape mesh between 2007 and 2009 at the Franziskus Krankenhaus, Berlin. The sample of the treated population represents the patient population for which the medical device is intended. To minimize selection bias without compromising patients' rights and welfare, all treated patients will be invited. These patients will be asked to participate in the validation of the questionnaire on quality of life. In addition to this safety and effectiveness of the surgical mesh implantation will be collected
- Intended to be treated with a mesh (Type: None): This arm of the study populations is defined by patients in whom a clinical anamnesis independent of the requirements of this study suggests that a sub-urethral sling operation is indicated. These patients will be asked to participate in the validation of the questionnaire on quality of life.
- Non-symptomatic Population (Type: None): This arm of the study population is defined by women that show no symptoms of incontinence. They will be asked to participate in the validation of the questionnaire on quality of life.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Japanese subject aged 20-70 years (both inclusive)~* Japanese passport holder~* Japanese-born parents~* Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months~* Treated with insulin for at least 3 months~* Body Mass Index (BMI) maximum 33.0 kg/m\^2~* Glycosylated haemoglobin A1c (HbA1c) maximum 10.0%~* Fasting C-peptide below 1.0 nmol/L~Exclusion Criteria:~* Use of oral antidiabetic drugs (OADs) and/or glucagon like peptide-1 (GLP-1) receptor agonists (exenatide, liraglutide) within 3 months prior to screening~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening~* Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period~* Supine blood pressure at screening (after resting for 5 min) minimum 180 mmHg for systolic and/or minimum 100 mmHg for diastolic

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- NN1250 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 years old or older.~2. A diagnosis of Chronic Lymphocytic Leukemia(CLL) which is CD5/CD19/CD23 positive, confirmed by peripheral blood immunophenotyping and/or lymph node biopsy and immunophenotyping and/or bone marrow biopsy and immunophenotyping. CD23-negative CLL cases are eligible, however additional diagnostic confirmation should include absence of Cyclin D1 rearrangement \[t(11;14)\] as determined by standard laboratory methods (such as fluorescent in situ hybridization).~3. Patients are planning to start chemotherapy for CLL recommended and prescribed by their primary oncologist.~4. Peripheral blood lymphocyte count above 20,000/mm3~5. Be able to provide written informed consent~Exclusion Criteria~1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.~2. Patients who are receiving any other investigational agents.~3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to vincristine.~4. Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~5. Liver function test abnormalities of ≥ grade 3 (total bilirubin \>3 ULN (upper limit of normal), AST\> 5 ULN, ALT\> 5 ULN) as per CTCAE 4.0 criteria, or direct bilirubin ≥ 3.0 mg/dL~6. Pre-existing neuropathy grade 2 or greater as per CTCAE 4.0 criteria (moderate symptoms limiting instrumental activities of daily living - ADLs)~7. Patients who are pregnant or planning to become pregnant during their participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vincrisitne 2mg (Type: EXPERIMENTAL): Single Arm study: Vincristine 2mg administered IV by infusion over 5 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Investigating the Best Method of Treatment of Bile Duct Stones in Higher Risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gallbladder stones~* At least strong evidence of bile duct stones (abnormal LFTs and dilated bile duct)~* Higher risk (\>70yrs, \>60yrs with co-morbidity, \>50 with BMI\>40)~Exclusion Criteria:~* Not fit for general anaesthesia~* Cholangitis requiring emergency ERCP~* Previous upper GI surgery making ERCP impossible

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gypenosides Treatment for Optic Neuritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Male and female Chinese patients aged ≥18 to ≤60 years~2. Patients with a first episode of optic neuritis in the eye of interest~3. First symptoms of optic neuritis ≤28 days prior to the first administration of investigational product~4. Best corrected visual acuity in the eye of interest ≤0.8~Exclusion criteria~1. Pre-existing multiple sclerosis MS or NMO~2. Refractive media opacity~3. Hyperopia \>5 diopters, myopia \<-5 diopters, or astigmatism \>3 diopters~4. Active tuberculosis, hepatitis, renal insufficiency, uncontrolled hypertension, diabetes mellitus, infection with HIV or syphilis, or any other conditions potentially interfering treatment trial~5. Other autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc)~6. Existing other retina or optic nerve diseases~7. Pregnant or females who plan to be pregnant during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Gypenosides (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Screening of Obstructive Sleep Apnea by Smartphone Homemade Video in Childood Snoring Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children between 3 and 10 years old consulting an ENT for snoring noted by the entourage (parents).~* Tonsil hypertrophy ≥ 2 (Brodsky classification).~* Entourage in possession of a smartphone allowing a video recording (under Android format).~Exclusion Criteria:~* Chronic cardiovascular, neurological, metabolic (overweight, obesity) or associated pulmonary pathology.~* Syndromic craniofacial malformations.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- children with adenoamygdala hypertrophy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TissuePAtchDS--P ™ PArotidectomy Trial.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients undergoing superficial parotidectomy for benign parotid disease.~2. Patients 18 years of age or above.~Exclusion Criteria:~1. American Society of Anesthesiologists (ASA) classification \>2 and/or Body Mass Index (BMI) \>35.~2. Any patient with malignant, infected/inflamed or recurrent parotid disease.~3. Patients taking immunosuppressants.~4. Patients with a history of allergic reaction to the composites of the patch~5. Previous parotid surgery to the same side.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Placement of TissuePatchDS-P™ at time of operation. No surgical drain is used.
- Control (Type: ACTIVE_COMPARATOR): No use of TissuePatchDS-P™. Wound is closed with a surgical drain (Surgeon's choice) in situ.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immobilization of Postoperative Distal Radius Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* extra and intra articular distal radius fractures treated with distal locking plates~Exclusion Criteria:~* patients with additional injuries to the ipsilateral wrist such as, distal radial ulnar joint (DRUJ) instability and associated unstable ulna fractures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Plaster Splint (Type: ACTIVE_COMPARATOR): None
- Velcro Brace (Type: ACTIVE_COMPARATOR): None
- Soft Dressing (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Deep Neural Networks on the Accuracy of Skin Disease Diagnosis in Non-Dermatologists

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* non-dermatologist physician (residents) who agree to participate in this study~Exclusion Criteria:~* dermatology residents~* non-dermatology residents who use other deep neural networks for skin lesion diagnosis

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DNN group (Type: EXPERIMENTAL): using deep neural networks for skin lesion diagnosis
- Control group (Type: NO_INTERVENTION): conventional diagnosis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Outcomes of Arteriovenous Fistula Cannulated From Different Direction.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MHD patients with autogenous AVF.~* Newly setup AVF in 3 months.~* Fore- or Upper arm AVF.~* Flow of \>800ml/min detected by using the ultrasound dilution technique.~Exclusion Criteria:~* AVF after neoplasty.~* Arteriovenous grafts.~* Anticipated live time less than one year.~* Patients whose concurrent illnesses, disability, or geographical residence would hamper attendance at required study visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Same direction cannulation (Type: EXPERIMENTAL): The inserted direction of arterial needle is same as the direction of blood flow.
- Opposite direction cannulation (Type: ACTIVE_COMPARATOR): The inserted direction of arterial needle is opposite to the direction of blood flow.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Psycho-Social Impact of Keloid

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Clinical Diagnosis of Keloid~2. Informed consent~3. Age above 18 to answer the survey questions~4. Parents shall respond on behalf of their minor children

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a diagnosis by the study investigator of a clinical syndrome of cognitive impairment consistent with prodromal AD per International Working Group (IWG) diagnostic criteria or mild cognitive impairment (MCI) due to AD per National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria.~* Scores 17-28 on Montreal Cognitive Assessment (MoCA) at screening.~* Scores \<27 on free recall cutoff score from the Free and Cued Selective Reminding Test (FCSRT) (Picture version) at screening.~* Scores ≤4 on Modified Hachinski Ischemia Scale (MHIS).~* Scores \>0 on the Functional Activities Questionnaire (FAQ).~* Has a florbetapir positron emission tomography (PET) scan or cerebrospinal fluid (CSF) result at screening consistent with the presence of amyloid pathology.~Exclusion Criteria:~* Has had MRI or computerized tomography (CT) of brain within previous 2 years showing pathology that would be inconsistent with a diagnosis of AD.~* Has known allergy to humanized monoclonal antibodies.~* Has an ongoing clinically significant laboratory abnormality, as determined by the investigator.~* Has screening MRI with results showing \>4 amyloid related imaging abnormalities H (ARIA-H) micro-hemorrhages or presence of ARIA-E.~* Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI.~* Has received treatment with a stable dose of an acetylcholinesterase (AChEI) inhibitor or memantine for less than 2 months before randomization. (If a participant has recently stopped AChEIs and/or memantine, he or she must have discontinued treatment at least 2 months before randomization.)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Solanezumab (Type: EXPERIMENTAL): Solanezumab given intravenously (IV) once every 4 weeks for up to 2 years.
- Placebo (Type: EXPERIMENTAL): Placebo given IV once every 4 weeks for up to 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NAFLD Activity Score(NAS) ≥ 3 (Biopsy-proven)~Exclusion Criteria:~* Alcohol consumption \> 20g/day~* Type 1 diabetes or poorly controlled diabetes mellitus (HbA1c ≥ 9%)~* Evidence of other chronic liver disease (e.g. HBsAg positive, anti-HCV positive, autoimmune hepatitis, Wilson's disease, alpha-1 antitrypsin deficiency and etc.)~* ALT, AST \> 5X the upper limit of normal~* Serum creatinine ≥ 2mg/dl~* Fibrosis score ≥ 3 according to the NASH CRN fibrosis staging system~* NQO1 T/T type~* Weight loss of more than 5kg within 6 months~* Bariatric surgery within 6 months~* Known alcohol or any other drug abuse in the last five years~* Insulin sensitizers, hepatoprotective agents, anti-oxidants, lipid-lowering agents, drugs induced fatty liver within 1 month

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- MB12066 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues